News

Life Sciences

PTC Therapeutics Acquiring Agilis and Gene Therapy Portfolio for $200 Million

PTC Therapeutics Acquiring Agilis and Gene Therapy Portfolio for $200 Million

Equities Research | Equities.com |

Deal includes $745 million in potential additional milestone payments based on success of Agilis' central nervous system therapies.


Morphosys and Galapagos Sign License Deal with Novartis in Inflammatory Disease

Equities Research | Equities.com |

Initial target is atopic dermatitis. Deal potentially worth $1.1 billion.


Geron's Imetelstat Reaffirmed as a Priority for Johnson & Johnson

Equities Research | Equities.com |

JNJ CEO Alex Gorsky cites hematology-related oncology among "key catalysts for growth."


SIGA Technologies Gets FDA Approval for First Smallpox Therapeutic

Equities Research | Equities.com |

Advances health security against a longstanding concern of smallpox as a potential bioterror threat. SIGA also gets priority review voucher for its next drug.


Crinetics Pharmaceuticals IPO Expected This Week For Rare Endocrine Disorders

Equities Research | Equities.com |

Initial targets include acromegaly, hyperinsulinemia and neuroendocrine tumors.


Allakos IPO Expected Next Week for Antibody Immunotherapy Programs

Equities Research | Equities.com |

Targeting receptors on eosinophils and mast cells to inhibit disease.


Zogenix Shows Positive Top-Line Results from 2nd Phase 3 Trial for Dravet Syndrome

Equities Research | Equities.com |

Confirmatory data shows significant reduction in convulsive seizures in patients with this severe form of epilepsy.


Otsuka Pharmaceuticals to Acquire Visterra for $430 Million

Equities Research | Equities.com |

Adding targeted antibody therapy platform and multiple kidney and infectious disease programs.


Constellation Pharmaceuticals Raising $80 Million in IPO to Advance Cancer Epigenetics

Equities Research | Equities.com |

Lead programs in prostate cancer, solid tumors and myelofibrosis.


Rubius Therapeutics IPO Expected Next Week to Advance Cellular Therapy Platform

Equities Research | Equities.com |

Initial focus on rare diseases, cancer and autoimmune diseases.


Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.

Events

The MoneyShow San Francisco

Why should you join thousands of America's savviest investors and traders who make The MoneyShow San Francisco their can't-miss conference each summer? Because you will meet face-to-face and hear from…

Learn more